Edwards Lifesciences has recalled more than 61,000 medical devices due to the risk of a small piece of wire becoming exposed. No patient injuries have been reported at this time.

This proposal, if finalized, would dramatically increase patient access to renal denervation. Both Recor Medical and Medtronic have shared their excitement over the news.

The 2026 MPFS proposed rule includes higher conversion factors across the board. However, some cardiology groups remain concerned about a series of reimbursement reductions for high-value cardiology services. 

The new guidelines detail the use of echocardiography to evaluate patients for a variety of conditions.

The ongoing debate continues. The team behind this latest analysis pointed to more than 40 years of research to make its point.

The use of advanced AI software to assess CCTA images continues to gain more momentum.

Caranx Medical is focused on using AI, robotics and other advanced technologies to expand patient access to life-saving procedures. This new software, for example, helps guide cardiologists through complex TAVR procedures.

Finerenone, sold by Bayer under the brand name Kerendia, is now approved in the United States for the treatment of HFmrEF and HFpEF. The drug has already been used for years to treat patients with chronic kidney disease and type 2 diabetes.

The first FDA-cleared AI model of its kind was found to be an accurate screening tool for cardiac amyloidosis.

The Varipulse PFA platform originally gained FDA approval in 2024. According to Johnson & Johnson MedTech, this update was put in place to help the technology provide better patient outcomes going forward.